<p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 首席财务官 Oluyemi Okupe 于 11 月 17 日星期一出售了 23,187 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 36.81 美元，总交易额为 853,513.47 美元。交易后，首席财务官直接持有该公司 70,232 股股票，估值约为 2,585,239.92 美元。这代表着他们持有的股票减少了 24.82%。此次出售在证券交易委员会的备案中披露，相关信息可通过此链接访问。</p>
<ul>
<li>HIMS 的股价波动如过山车。投资者应该入场吗？</li>
</ul>
<p>Oluyemi Okupe 最近还进行了以下交易：</p>
<ul>
<li>在 11 月 17 日星期一，Oluyemi Okupe 出售了 23,187 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 36.81 美元，总价值为 853,513.47 美元。</li>
<li>在 10 月 17 日星期五，Oluyemi Okupe 出售了 11,592 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 57.13 美元，总价值为 662,250.96 美元。</li>
<li>在 10 月 3 日星期五，Oluyemi Okupe 出售了 11,595 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 57.72 美元，总价值为 669,263.40 美元。</li>
<li>在 9 月 29 日星期一，Oluyemi Okupe 出售了 85,000 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 60.20 美元，总价值为 5,117,000.00 美元。</li>
<li>在 9 月 22 日星期一，Oluyemi Okupe 出售了 23,584 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 57.74 美元，总价值为 1,361,740.16 美元。</li>
<li>在 9 月 15 日星期一，Oluyemi Okupe 出售了 145,000 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 55.35 美元，总交易额为 8,025,750.00 美元。</li>
<li>在 8 月 26 日星期二，Oluyemi Okupe 出售了 11,581 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 43.69 美元，总交易额为 505,973.89 美元。</li>
</ul>
<p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
<h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 1.2%</p>
<p>Hims
&amp; Hers Health 股票在星期三下跌 0.45 美元，跌至 35.81 美元。该公司的交易量为 20,738,539 股，而其平均交易量为 32,329,717 股。该股票的 50 日移动平均线为 50.12 美元，200 日移动平均线为 51.42 美元。该公司的债务与股本比率为 1.67，流动比率为 1.88，速动比率为 1.64。Hims
&amp; Hers Health, Inc. 的 12 个月低点为 21.36 美元，12 个月高点为 72.98 美元。该公司的市值为 81.5 亿美元，市盈率为 66.31，市盈增长比率为 7.08，贝塔值为 2.20。</p>
<ul>
<li>为什么 Hims
&amp; Hers 股票在第三季度业绩不佳后可能是一个买入机会</li>
</ul>
<p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近一次发布季度财报是在 11 月 3 日星期一。该公司报告本季度每股收益为 0.06 美元，低于市场共识预期的 0.09 美元，差额为 0.03 美元。该公司本季度的收入为 5.9898 亿美元，而市场共识预期为 5.7899 亿美元。Hims
&amp; Hers Health 的净利润率为 6.05%，股本回报率为 24.67%。与去年同期相比，该公司的收入增长了 49.2%。在去年同期，该公司每股收益为 0.32 美元。Hims
&amp; Hers Health 已设定 2025 财年的每股收益指导。2025 财年第四季度的每股收益指导。研究分析师预测 Hims
&amp; Hers Health, Inc. 本年度每股收益将达到 0.29 美元。</p>
<p>Hims
&amp; Hers Health 宣布其董事会已于 11 月 17 日星期一批准了一项股票回购计划，允许公司回购 2.5 亿美元的流通股。该回购授权允许公司通过公开市场购买回购最多 3% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>机构资金流入和流出</h2>
<ul>
<li>Hims
&amp; Hers 的空头头寸接近历史高点，是否应该趁机买入？</li>
</ul>
<p>一些大型投资者最近买入和卖出了该股票的股份。Farallon Capital Management LLC 在第三季度将其在 Hims
&amp; Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有该公司 10,746,852 股股票，价值 609,561,000 美元，在此期间又购买了 2,533,271 股。Invesco Ltd. 在第二季度将其在 Hims
&amp; Hers Health 的股份增加了 502.2%。Invesco Ltd. 目前持有该公司 2,552,405 股股票，价值 127,237,000 美元，在上个季度又购买了 2,128,587 股。Nuveen LLC 在第一季度获得了 Hims
&amp; Hers Health 的新股份，价值 58,403,000 美元。Clear Street LLC 在第二季度购买了 Hims
&amp; Hers Health 的新股份，价值 83,582,000 美元。最后，挪威银行在第二季度获得了 Hims
&amp; Hers Health 的新股份，价值约 78,464,000 美元。机构投资者和对冲基金持有该公司 63.52% 的股份。</p>
<h2>分析师评级上调和下调</h2>
<p>多家研究公司最近发布了关于 HIMS 的报告。瑞银集团在 11 月 4 日的报告中对 Hims &amp; Hers Health 设定了 32.00 美元的目标价。Needham &amp; Company LLC 在 8 月 5 日的研究报告中重申了对 Hims &amp; Hers Health 股票的 “持有” 评级。BTIG Research 在 11 月 4 日的研究报告中重新发布了 “买入” 评级，并对 Hims &amp; Hers Health 股票设定了 85.00 美元的目标价。美国银行在 11 月 4 日的研究报告中将 Hims &amp; Hers Health 股票的目标价从 28.00 美元上调至 32.00 美元，并给予该公司 “表现不佳” 的评级。最后，Zacks Research 在 8 月 19 日的研究报告中将 Hims &amp; Hers Health 股票的评级从 “强力买入” 下调至 “持有”。两位投资分析师给予该股票 “买入” 评级，十位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “减持”，共识目标价为 45.27 美元。</p>
<p><strong>阅读我们关于 Hims &amp; Hers Health 的最新报告</strong></p>
<h2>关于 Hims &amp; Hers Health</h2>
<p>(获取免费报告)</p>
<p>Hims &amp; Hers Health, Inc.运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Hims &amp; Hers Health</li>
<li>为什么投资高收益分红股票？</li>
<li>HIMS 经历了过山车般的旅程。投资者应该上车吗？</li>
<li>复利是如何计算的？</li>
<li>以这三只反弹冠军强势结束年末</li>
<li>如何计算期权利润</li>
<li>诺和诺德年初至今下跌 45%，引发价格战</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Hims &amp; Hers Health 吗？</h2>
<p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Hims &amp; Hers Health 并不在名单上。</p>
<p>虽然 Hims &amp; Hers Health 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HIMS

<p>Hims & Hers Health 首席财务官 Oluyemi Okupe 出售了 23,187 股，每股价格为 36.81 美元，总计 853,513.47 美元，减少了 24.82% 的持股比例。公司宣布了一项 2.5 亿美元的股票回购计划，表明其被低估。最近的财报未能达到预期，但收入同比增长了 49.2%。该股票价格波动较大，12 个月的最低价为 21.36 美元，最高价为 72.98 美元。机构投资者正在积极交易该股票</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 23,187 shares of Hims &amp; Hers Health stock in a transaction on Monday, November 17th. The stock was sold at an average price of $36.81, for a total transaction of $853,513.47. Following the transaction, the chief financial officer directly owned 70,232 shares in the company, valued at approximately $2,585,239.92. This represents a 24.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health, Inc. (NYSE:HIMS - 获取免费报告) 首席财务官 Oluyemi Okupe 于 11 月 17 日星期一出售了 23,187 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 36.81 美元，总交易额为 853,513.47 美元。交易后，首席财务官直接持有该公司 70,232 股股票，估值约为 2,585,239.92 美元。这代表着他们持有的股票减少了 24.82%。此次出售在证券交易委员会的备案中披露，相关信息可通过此链接访问。</p>
</div><ul>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
</ul>
<div class="lb-trans"><ul>
<li>HIMS 的股价波动如过山车。投资者应该入场吗？</li>
</ul>
</div><p>Oluyemi Okupe also recently made the following trade(s):</p>
<div class="lb-trans"><p>Oluyemi Okupe 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $36.81, for a total value of $853,513.47.</li>
<li>On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $57.13, for a total value of $662,250.96.</li>
<li>On Friday, October 3rd, Oluyemi Okupe sold 11,595 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $57.72, for a total value of $669,263.40.</li>
<li>On Monday, September 29th, Oluyemi Okupe sold 85,000 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $60.20, for a total value of $5,117,000.00.</li>
<li>On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $57.74, for a total value of $1,361,740.16.</li>
<li>On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $55.35, for a total transaction of $8,025,750.00.</li>
<li>On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $43.69, for a total transaction of $505,973.89.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 11 月 17 日星期一，Oluyemi Okupe 出售了 23,187 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 36.81 美元，总价值为 853,513.47 美元。</li>
<li>在 10 月 17 日星期五，Oluyemi Okupe 出售了 11,592 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 57.13 美元，总价值为 662,250.96 美元。</li>
<li>在 10 月 3 日星期五，Oluyemi Okupe 出售了 11,595 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 57.72 美元，总价值为 669,263.40 美元。</li>
<li>在 9 月 29 日星期一，Oluyemi Okupe 出售了 85,000 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 60.20 美元，总价值为 5,117,000.00 美元。</li>
<li>在 9 月 22 日星期一，Oluyemi Okupe 出售了 23,584 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 57.74 美元，总价值为 1,361,740.16 美元。</li>
<li>在 9 月 15 日星期一，Oluyemi Okupe 出售了 145,000 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 55.35 美元，总交易额为 8,025,750.00 美元。</li>
<li>在 8 月 26 日星期二，Oluyemi Okupe 出售了 11,581 股 Hims
&amp; Hers Health 股票。该股票的平均售价为 43.69 美元，总交易额为 505,973.89 美元。</li>
</ul>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Hims
&amp; Hers Health</strong> 的提醒：</p>
</div><h2>Hims &amp; Hers Health Stock Down 1.2%</h2>
<div class="lb-trans"><h2>Hims</h2>
<p>&amp; Hers Health 股票下跌 1.2%</p>
</div><p>Shares of Hims &amp; Hers Health stock traded down $0.45 on Wednesday, hitting $35.81. The company had a trading volume of 20,738,539 shares, compared to its average volume of 32,329,717. The stock has a 50-day moving average of $50.12 and a 200-day moving average of $51.42. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. Hims &amp; Hers Health, Inc. has a twelve month low of $21.36 and a twelve month high of $72.98. The firm has a market capitalization of $8.15 billion, a P/E ratio of 66.31, a P/E/G ratio of 7.08 and a beta of 2.20.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health 股票在星期三下跌 0.45 美元，跌至 35.81 美元。该公司的交易量为 20,738,539 股，而其平均交易量为 32,329,717 股。该股票的 50 日移动平均线为 50.12 美元，200 日移动平均线为 51.42 美元。该公司的债务与股本比率为 1.67，流动比率为 1.88，速动比率为 1.64。Hims
&amp; Hers Health, Inc. 的 12 个月低点为 21.36 美元，12 个月高点为 72.98 美元。该公司的市值为 81.5 亿美元，市盈率为 66.31，市盈增长比率为 7.08，贝塔值为 2.20。</p>
</div><ul>
<li>Why Hims &amp; Hers Stock May Be a Buy After Mixed Q3 Results</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 Hims
&amp; Hers 股票在第三季度业绩不佳后可能是一个买入机会</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims &amp; Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company's revenue was up 49.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.32 earnings per share. Hims &amp; Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts predict that Hims &amp; Hers Health, Inc. will post 0.29 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health (NYSE:HIMS - 获取免费报告) 最近一次发布季度财报是在 11 月 3 日星期一。该公司报告本季度每股收益为 0.06 美元，低于市场共识预期的 0.09 美元，差额为 0.03 美元。该公司本季度的收入为 5.9898 亿美元，而市场共识预期为 5.7899 亿美元。Hims
&amp; Hers Health 的净利润率为 6.05%，股本回报率为 24.67%。与去年同期相比，该公司的收入增长了 49.2%。在去年同期，该公司每股收益为 0.32 美元。Hims
&amp; Hers Health 已设定 2025 财年的每股收益指导。2025 财年第四季度的每股收益指导。研究分析师预测 Hims
&amp; Hers Health, Inc. 本年度每股收益将达到 0.29 美元。</p>
</div><p>Hims &amp; Hers Health announced that its Board of Directors has approved a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.</p>
<div class="lb-trans"><p>Hims
&amp; Hers Health 宣布其董事会已于 11 月 17 日星期一批准了一项股票回购计划，允许公司回购 2.5 亿美元的流通股。该回购授权允许公司通过公开市场购买回购最多 3% 的股票。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><ul>
<li>Hims &amp; Hers Short Interest Nears All-Time High, Buy The Dip?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims
&amp; Hers 的空头头寸接近历史高点，是否应该趁机买入？</li>
</ul>
</div><p>A number of large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC raised its position in Hims &amp; Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company's stock valued at $609,561,000 after purchasing an additional 2,533,271 shares during the period. Invesco Ltd. grew its stake in shares of Hims &amp; Hers Health by 502.2% in the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company's stock valued at $127,237,000 after buying an additional 2,128,587 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Hims &amp; Hers Health in the first quarter valued at $58,403,000. Clear Street LLC purchased a new stake in shares of Hims &amp; Hers Health in the 2nd quarter valued at $83,582,000. Finally, Norges Bank acquired a new position in Hims &amp; Hers Health during the 2nd quarter worth about $78,464,000. Institutional investors and hedge funds own 63.52% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近买入和卖出了该股票的股份。Farallon Capital Management LLC 在第三季度将其在 Hims
&amp; Hers Health 的持股增加了 30.8%。Farallon Capital Management LLC 目前持有该公司 10,746,852 股股票，价值 609,561,000 美元，在此期间又购买了 2,533,271 股。Invesco Ltd. 在第二季度将其在 Hims
&amp; Hers Health 的股份增加了 502.2%。Invesco Ltd. 目前持有该公司 2,552,405 股股票，价值 127,237,000 美元，在上个季度又购买了 2,128,587 股。Nuveen LLC 在第一季度获得了 Hims
&amp; Hers Health 的新股份，价值 58,403,000 美元。Clear Street LLC 在第二季度购买了 Hims
&amp; Hers Health 的新股份，价值 83,582,000 美元。最后，挪威银行在第二季度获得了 Hims
&amp; Hers Health 的新股份，价值约 78,464,000 美元。机构投资者和对冲基金持有该公司 63.52% 的股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调和下调</h2>
</div><p>A number of research firms recently issued reports on HIMS. UBS Group set a $32.00 price objective on Hims &amp; Hers Health in a report on Tuesday, November 4th. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Hims &amp; Hers Health in a research note on Tuesday, August 5th. BTIG Research reissued a &#34;buy&#34; rating and issued a $85.00 price objective on shares of Hims &amp; Hers Health in a research report on Tuesday, November 4th. Bank of America raised their target price on shares of Hims &amp; Hers Health from $28.00 to $32.00 and gave the company an &#34;underperform&#34; rating in a research report on Tuesday, November 4th. Finally, Zacks Research cut shares of Hims &amp; Hers Health from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 19th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Reduce&#34; and a consensus price target of $45.27.</p>
<div class="lb-trans"><p>多家研究公司最近发布了关于 HIMS 的报告。瑞银集团在 11 月 4 日的报告中对 Hims &amp; Hers Health 设定了 32.00 美元的目标价。Needham &amp; Company LLC 在 8 月 5 日的研究报告中重申了对 Hims &amp; Hers Health 股票的 “持有” 评级。BTIG Research 在 11 月 4 日的研究报告中重新发布了 “买入” 评级，并对 Hims &amp; Hers Health 股票设定了 85.00 美元的目标价。美国银行在 11 月 4 日的研究报告中将 Hims &amp; Hers Health 股票的目标价从 28.00 美元上调至 32.00 美元，并给予该公司 “表现不佳” 的评级。最后，Zacks Research 在 8 月 19 日的研究报告中将 Hims &amp; Hers Health 股票的评级从 “强力买入” 下调至 “持有”。两位投资分析师给予该股票 “买入” 评级，十位分析师给予 “持有” 评级，三位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “减持”，共识目标价为 45.27 美元。</p>
</div><p><strong>Read Our Latest Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Hims &amp; Hers Health 的最新报告</strong></p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>关于 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Hims &amp; Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc.运营一个远程医疗咨询平台。它将消费者与医疗专业人员连接，使他们能够获得心理健康、性健康、皮肤病和初级护理的医疗服务。该公司成立于 2017 年，总部位于加利福尼亚州旧金山。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li>
<li>How is Compound Interest Calculated?</li>
<li>End the Year Strong With These 3 Comeback Champions</li>
<li>How to Calculate Options Profits</li>
<li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Hims &amp; Hers Health</li>
<li>为什么投资高收益分红股票？</li>
<li>HIMS 经历了过山车般的旅程。投资者应该上车吗？</li>
<li>复利是如何计算的？</li>
<li>以这三只反弹冠军强势结束年末</li>
<li>如何计算期权利润</li>
<li>诺和诺德年初至今下跌 45%，引发价格战</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Hims &amp; Hers Health 吗？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Hims &amp; Hers Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Hims &amp; Hers Health 并不在名单上。</p>
</div><p>While Hims &amp; Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Hims &amp; Hers Health 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Hims & Hers Health（NYSE:HIMS）的首席财务官 Oluyemi Okupe 出售了 23,187 股股票